Genmab soars to record highs after cancer drug succeeds in key trial
Source: BioPharma Dive - Latest News
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.